Status:

COMPLETED

Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease

Lead Sponsor:

Vanderbilt University Medical Center

Collaborating Sponsors:

VA Tennessee Valley Health Care System

Conditions:

Chronic Kidney Diseases

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

Chronic kidney disease (CKD) is a burden of morbidity and mortality. Increased protein breakdown in skeletal muscle (wasting) and ectopic fat deposition are important determinants of poor clinical out...

Eligibility Criteria

Inclusion

  • Patients with stage 3-4 CKD (eGFR 15-59 ml/min/1/73 m2)
  • Age ≥ 18 years and ≤75 years

Exclusion

  • Patients with type 1 diabetes mellitus
  • Patients with T2D who are on insulin therapy or who started a new antidiabetic medication within 1 month prior to study or who received incretin-based therapy within 3 months prior to study
  • BMI \<25 kg/m2, BMI \>40 kg/m2
  • HbA1c\>8% measured within 1 month prior to study, or a history of hypoglycemic episode within 1 year prior to study, or a history of diabetic ketoacidosis
  • Uncontrolled hypertension (\>200/100 mmHg) despite optimal antihypertensive therapy
  • Arrythmia, heart failure (NYHA class III-IV), valve disease or heart diseases other than coronary artery disease
  • History of major gastrointestinal surgery, inflammatory bowel disease, pancreatitis or cholelithiasis
  • Personal or family history of medullary thyroid cancer, or personal history of Multiple Endocrine Neoplasia (MEN)-2
  • Pregnancy, breast feeding or intention to become pregnant
  • Previous renal transplantation
  • Acute or chronic infectious diseases
  • Cancer or chemotherapy within 3 years prior to study
  • Treatment with systemic corticosteroids within 3 months prior to study
  • Known or suspected allergy to dulaglutide
  • Claustrophobia or other contraindications for magnetic resonance imaging

Key Trial Info

Start Date :

March 15 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2024

Estimated Enrollment :

7 Patients enrolled

Trial Details

Trial ID

NCT05254418

Start Date

March 15 2022

End Date

August 1 2024

Last Update

April 20 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232